Top

Published in:

Open Access 01-01-2020 | Parkinson's Disease | Neurological Update

New awakenings: current understanding of sleep dysfunction and its treatment in Parkinson’s disease

Authors: Lindsay H. M. Keir, David P. Breen

Published in: Journal of Neurology | Issue 1/2020

Abstract

The non-motor features of Parkinson’s disease (PD) are increasingly being recognised. This review deals with the spectrum of sleep disorders associated with PD, which have a multifactorial aetiology and can significantly have an impact on the quality of life of patients and their carers. Some sleep disorders represent a prodromal phase of PD, with REM sleep behaviour disorder (RBD) being of particular interest in this regard, whereas others become more common as the disease advances. Understanding the pathophysiology of these sleep disturbances will hopefully lead to new treatment opportunities in the future. The recent discovery of the glymphatic system for removal of waste products from the brain has also raised the possibility that sleep disruption may cause or accelerate the underlying disease process.

Abbott RD, Ross GW, White LR et al (2005) Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 65(9):1442–1446PubMed

Allen RP, Chen C, Garcia-Borreguero D et al (2014) Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med 370(7):621–631PubMed

Barone P, Antonini A, Colosimo C et al (2009) The Priamo study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24(11):1641–1649PubMed

Barber TR, Lawton M, Rolinski M et al (2017) Prodromal Parkinsonism and neurodegenerative risk stratification in REM sleep behaviour disorder. Sleep 40(8):1093

Becker PM, Novak M (2014) Diagnosis, comorbidities, and management of restless legs syndrome. Curr Med Res Opin 30(8):1441–1460PubMed

Boddy F, Rowan EN, Lett D et al (2007) Subjectively reported sleep quality and excessive daytime somnolence in Parkinson's disease with and without dementia, dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 22:529–535PubMed

Breen DP, Williams-Gray CH, Mason SL et al (2012) Excessive daytime sleepiness and its risk factors in incident Parkinson's disease. J Neurol Neurosurg Psychiatry 84(2):233–234PubMed

Breen DP, Vuono R, Nawarathna U et al (2014) Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol 71(5):589–595PubMedPubMedCentral

Breen DP, Nombela C, Vuono R et al (2016) Hypothalamic volume loss. Is associated with reduced melatonin output in Parkinson’s disease. Mov Disord 31(7):1062–1066PubMedPubMedCentral

10.

Camacho-Soto A, Warden MN, Searles Nielsen S et al (2017) Traumatic brain injury in the prodromal period of Parkinson’s disease: a large epidemiological study using Medicare data. Ann Neurol 82(5):744–754PubMedPubMedCentral

11.

Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8(5):464–474PubMed

12.

Chiu HF, Wing YK, Lam LC et al (2000) Sleep-related injury in the elderly: an epidemiological study in Hong Kong. Sleep 23:513–517PubMed

13.

Connor JR, Wang ZS, Allen RP et al (2009) Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain 132:2403–2412PubMedPubMedCentral

14.

Covassin N, Neikrug AB, Liu L et al (2012) Clinical correlates of periodic limb movements in sleep in Parkinson’s disease. J Neurol Sci 316(1–2):131–136PubMedPubMedCentral

15.

Cochen De Cock VC, Abouda M, Leu S et al (2010) Is obstructive sleep apnea a problem in Parkinson’s disease? Sleep Med 11(3):247–252PubMed

16.

Dowling GA, Mastick J, Colling E et al (2005) Melatonin for sleep disturbances in Parkinson’s disease. Sleep Med 6(5):459–466PubMed

17.

Fronczek R, Overeem S, Lee SY et al (2007) Hypocretin (orexin) loss in Parkinson’s disease. Brain 130(6):1577–1585PubMed

18.

Gallagher DA, Lees AJ, Schrag A (2010) What are the most important nonmotor symptoms in patients with Parkinson’s disease and why are we missing them? Mov Disord 25(15):2493–2500PubMed

19.

Gao J, Huang X, Park Y et al (2011) Daytime napping, nighttime sleeping and Parkinson disease. Am J Epidemiol 173(9):1032–1038PubMedPubMedCentral

20.

Garcia SV, Libourel PA, Lazarus M et al (2017) Genetic inactivation of glutamate neurons in the rat sublaterodorsal tegmental nucleus recapitulates REM sleep behaviour disorder. Brain 140(2):414–428

21.

Garcia-Borreguero D, Silber MH, Winkelman JW et al (2016) Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS Foundation. Sleep Med 21:1–11PubMed

22.

Garcia-Lorenzo D, Longo-Dos Santos C, Ewencyzk C et al (2013) The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson’s disease. Brain 136(7):2120–2129PubMedPubMedCentral

23.

Gilat M, Jackson AC, Marshall NS et al (2019) Melatonin for rapid eye movement sleep behaviour disorder in Parkinson’s disease: a randomised controlled trial. Mov Disord. https://doi.org/10.1002/mds.27886 CrossRefPubMed

24.

Gjerstad MD, Alves G, Wentzel-Larsen T (2006) Excessive daytime sleepiness in Parkinson disease. Is it the drugs or the disease? Neurology 67(5):853–858PubMed

25.

Harnois C, Di Paolo T (1990) Decreased dopamine in the retinas of patients with Parkinson’s disease. Invest Ophthalmol Vis Sci 31(11):2473–2475PubMed

26.

Holth JK, Fritschi SK, Wang C et al (2019) The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science 363:880–884PubMed

27.

Homann CN, Wenzel K, Suppan K et al (2002) Sleep attacks in patients taking dopamine agonists. BMJ 324(7352):1483–1487PubMedPubMedCentral

28.

Iliff JJ, Chen MJ, Plog BA et al (2014) Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. J Neurosci 34(49):16180–16193PubMedPubMedCentral

29.

Iliff JJ, Wang M, Liao Y et al (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial Solutes, including amyloid beta. Sci Transl Med 4(147):147

30.

Kalaitzakis ME, Gentleman SM, Pearce RKB (2013) Disturbed sleep in Parkinson’s disease: anatomical and pathological correlates. Neuropathol Appl Neurobiol 39(6):644–653PubMed

31.

Kang S-H, Yoon IT, Lee SD et al (2013) REM sleep behaviour disorder in the Korean elderly population: prevalence and clinical characteristics. Sleep 36(8):1147–1152PubMedPubMedCentral

32.

Kress BA, Iliff JJ, Xia M et al (2014) Impairment of paravascular clearance pathways in the aging brain. Ann Neurol 76(6):845–861PubMedPubMedCentral

33.

Kunz D, Mahlberg R (2010) A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res 19(4):591–596PubMed

34.

Kurtis MM, Balestrino R, Rodriguez-Blazquez C et al (2018) A review of scales to evaluate sleep disturbances in movement disorders. Front Neurol 9(369):3389

35.

Li SX, Lam SP, Zhang J et al (2016) A prospective, naturalistic follow-up study of treatment outcomes with clonazepam in rapid eye movement sleep behaviour disorder. Sleep Med 21:114–120PubMed

36.

Li W, Ma L, Yang G, Gan W-B (2017) REM sleep selectively prunes and maintains new synapses in development and learning. Nat Neurosci 20:427–437PubMedPubMedCentral

37.

Lucey BP, Hicks TJ, McLeland JS et al (2018) Effect of sleep on overnight cerebrospinal fluid amyloid beta kinetics. Ann Neurol 83(1):197–204PubMedPubMedCentral

38.

Lysen TS, Darweesh SKL, Ikram MK et al (2019) Sleep and risk of parkinsonism and Parkinson’s disease: a population-based study. Brain 142(7):2013–2022PubMedPubMedCentral

39.

Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM et al (2011) The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord 26(3):399–406PubMed

40.

Martino JK, Freelance CB, Willis GL (2018) The effect of light exposure on insomnia and nocturnal movement in Parkinson’s disease: an open label, retrospective, longitudinal study. Sleep Med 44:24–31PubMed

41.

Medeiros CA, Carvalhedo de Bruin PF, Lopes LA et al (2007) Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson’s disease. A randomized, double blind, placebo-controlled study. J Neurol 254(4):459–464PubMed

42.

Meindorfner C, Komer Y, Moller JC et al (2005) Driving in Parkinson’s disease: mobility, accidents, and sudden onset of sleep at the wheel. Mov Disord 20(7):832–842PubMed

43.

Montplaisir J, Boucher S, Poirier G et al (1997) Clinical, polysomnographic and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 12(1):61–65PubMed

44.

Noyce AJ, Kia DA, Heilbron K et al (2018) Tendency towards being a “Morning person” increases the risk of Parkinson’s disease: evidence from Mendelian randomisation. BioRxiv. https://doi.org/10.1101/288241 CrossRef

45.

Ohayon and Roth (2002) Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res 53(1):547–554PubMed

46.

Ondo WG, Vuong KD, Jankovic J (2002) Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol 59(3):421–424PubMed

47.

Paus S, Brecht HM, Koster J et al (2003) Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson’s disease. Mov Disord 18(6):659–667PubMed

48.

Peeraully T, Yong MH, Chokroverty S, Tan EK (2012) Sleep and Parkinson’s disease: a review of case–control polysomnography studies. Mov Disord 27(14):1729–1737PubMed

49.

Poewe W (2017) Parkinson disease. Nat Rev Dis Primers 3:17013PubMed

50.

Postuma RB, Gagnon JF, Tuineaig M et al (2013) Antidepressants and REM sleep behaviour disorder: isolated side effect or neurodegenerative signal? Sleep 36(11):1579–1585PubMedPubMedCentral

51.

Postuma RB, Iranzo A, Hu M et al (2019) Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multi centre study. Brain 142:744–759PubMedPubMedCentral

52.

Raven F, Van der Zee EA, Meerlo P, Havekes R (2018) The role of sleep in regulating structural plasticity and synaptic strength: Implications for memory and cognitive function. Sleep Med Rev 39:3–11PubMed

53.

Schenk CH, Boeve BF, Mahowald MW (2013) Delayed emergence of a parkinsonism disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder: a 16-year update on a previously reported series. Sleep Med 14(8):744–748

54.

Seppi K, Ray Chaudhuri K, Coelho M et al (2019) Update on treatments for nonmotor symptoms of Parkinson’s disease—an evidence based medicine review. Mov Disord 34(2):180–198PubMedPubMedCentral

55.

Shokri-Kojiri E, Wang G-J, Wiers CE et al (2018) β-Amyloid accumulation in the human brain after one night of sleep deprivation. PNAS 115(17):4483–4488

56.

Sohail S, Yu L, Schneider JA et al (2017) Sleep fragmentation and Parkinson’s disease pathology in older adults without Parkinson’s disease. Mov Disord 32(12):1729–1737PubMedPubMedCentral

57.

Speelman AD, van de Warrenburg BP, van Nimwegen M et al (2011) How might physical activity benefit patients with Parkinson disease? Nat Rev Neurol 7:528–534PubMed

58.

Stepanski EJ, Wyatt JK (2003) Use of sleep hygiene in the treatment of insomnia. Sleep Med Rev 7(3):215–225PubMed

59.

Thannickal TC, Lai YY, Siegel JM (2007) Hypocretin (orexin) cell loss in Parkinson’s disease. Brain 130(6):1586–1595PubMed

60.

Tononi G, Cirelli C (2014) Sleep and the price of plasticity: from synaptic and cellular homeostasis to memory consolidation and integration. Neuron 81(10):12–34PubMedPubMedCentral

61.

Trotti LM, Bliwise DL (2010) No increased risk of obstructive sleep apnea in Parkinson’s disease. Mov Disord 25(13):2246–2249PubMedPubMedCentral

62.

Videnovic A, Noble C, Reid KJ et al (2014) Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson’s disease. JAMA Neurol 71(4):463–469PubMedPubMedCentral

63.

Videnovic A, Lazar AS, Barker RA, Overeem S (2014) “The clocks that time us”—circadian rhythms in neurodegenerative disorders. Nat Rev Neurol 10(2):683–693PubMedPubMedCentral

64.

Videnovic A (2017) Management of sleep disorders in Parkinson’s disease and multiple system atrophy. Mov Disord 32(5):659–668PubMedPubMedCentral

65.

Videnovic A, Klerman ED, Wang W et al (2017) Timed light therapy for sleep and daytime sleepiness associated with Parkinson disease: a randomized clinical trial. JAMA Neurol 4(4):411–418

66.

Vincken WG, Gauthier SG, Dollfuss RE et al (1984) Involvement of upper-airway muscles in extrapyramidal disorders—a cause of airflow limitation. New Engl J Med 311:438–442PubMed

67.

Wienecke M, Werth E, Poryazova R et al (2012) Progressive dopamine and hypocretin deficiencies in Parkinson’s disease: is there an impact on sleep and wakefulness? J Sleep Res 21(6):710–717PubMed

68.

Winkelman JW, Armstrong MJ, Allen RP et al (2016) Practice guideline summary: treatment of restless legs syndrome in adults: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 87(24):2585–2593PubMedPubMedCentral

69.

Xie L, Kang H, Xu Q et al (2013) Sleep drives metabolite clearance from the adult brain. Science 342(6156):373–377PubMed

70.

Yaffe K, Falvey CM, Hoang T (2014) Connections between sleep and cognition in older adults. Lancet Neurol 13(10):1017–1028PubMed

71.

Yang X, Liu B, Shen H et al (2018) Prevalence of restless legs syndrome in Parkinson’s disease: a systematic review and meta-analysis of observational studies. Sleep Med 43:40–46PubMed

72.

Youngstedt SD, O’Connor PJ, Dishman RK (1997) The effects of acute exercise on sleep: a quantitative synthesis. Sleep 20:203–214PubMed

Title: New awakenings: current understanding of sleep dysfunction and its treatment in Parkinson’s disease
Authors: Lindsay H. M. Keir
David P. Breen
Publication date: 01-01-2020
Publisher: Springer Berlin Heidelberg
Keyword: Parkinson's Disease
Published in: Journal of Neurology / Issue 1/2020
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-019-09651-z

At a glance: The STEP trials

Springer Medicine

New awakenings: current understanding of sleep dysfunction and its treatment in Parkinson’s disease

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Apathy as a behavioural marker of cognitive impairment in Parkinson’s disease: a longitudinal analysis

Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS

European muscle MRI study in limb girdle muscular dystrophy type R1/2A (LGMDR1/LGMD2A)

Clinical features distinguish cerebral amyloid angiopathy-associated convexity subarachnoid haemorrhage from suspected TIA

Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders

Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen